Method for monitoring early treatment response

Details Method for monitoring early treatment response Method for monitoring early treatment response

2005-02-08

2009-11-24

Jones, D L (Department: 1618)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Magnetic imaging agent

C424S001110, C424S001650, C424S001810, C424S009100, C424S009200

Reexamination Certificate

active

07622102

ABSTRACT:
Disclosed is a method for monitoring early treatment response of a cancer treatment comprising measuring by magnetic resonance spectroscopy (MRS), for example, proton MRS, the amount of Choline present in the tissue adjoining or surrounding the cancerous tissue before and after treatment; the treatment comprises administration of an angiogenesis inhibitor, for example, a VEGF inhibitor, whereby a decrease in the amount of Choline after treatment is indicative of a positive response. The decrease in the amount of Choline represents the decrease in the internal cell membrane as a result of down regulation of the organelles and their secretory granules and their transport vesicles. Disclosed also is a method for determining effectiveness of an angiogenesis inhibitor in the treatment of cancer. Also disclosed are methods of monitoring early treatment response in diseases where an angiogenesis effector, i.e., an inhibitor or promoter of angiogenesis, is employed.

REFERENCES:
patent: 4354499 (1982-10-01), Damadian
patent: 4411270 (1983-10-01), Damadian
patent: RE32619 (1988-03-01), Damadian
patent: RE32689 (1988-06-01), Damadian
patent: 4843321 (1989-06-01), Sotak
patent: 4962357 (1990-10-01), Sotak
patent: 5111819 (1992-05-01), Hurd
patent: 5200345 (1993-04-01), Young
patent: 5498421 (1996-03-01), Grinstaff et al.
patent: 5578921 (1996-11-01), Morrell
patent: 5585118 (1996-12-01), Stoll
patent: 5617861 (1997-04-01), Ross et al.
patent: 5887588 (1999-03-01), Usenius et al.
patent: 5903149 (1999-05-01), Gonen et al.
patent: 6046589 (2000-04-01), Lamerichs et al.
patent: 6181134 (2001-01-01), Wald
patent: 6280383 (2001-08-01), Damadian
patent: 6347239 (2002-02-01), Arnold et al.
patent: 6400150 (2002-06-01), Liu et al.
patent: 6617169 (2003-09-01), Ke et al.
patent: 6630125 (2003-10-01), DeGrado et al.
patent: 6639405 (2003-10-01), Liu et al.
patent: 6681132 (2004-01-01), Katz et al.
patent: 6708053 (2004-03-01), Brooks et al.
patent: 6756063 (2004-06-01), Kiss
patent: 6819952 (2004-11-01), Pfefferbaum et al.
patent: 6838877 (2005-01-01), Heid et al.
patent: 7289840 (2007-10-01), Norfray
patent: 2001/0003423 (2001-06-01), Wald
patent: 2002/0142367 (2002-10-01), Ke et al.
patent: 2002/0173713 (2002-11-01), Pfefferbaum et al.
patent: 2003/0028093 (2003-02-01), Ke et al.
patent: 2003/0199751 (2003-10-01), Gonzalez et al.
patent: 2003/0208120 (2003-11-01), Thomas et al.
patent: 2003/0214292 (2003-11-01), Heid et al.
patent: 2004/0092809 (2004-05-01), DeCharms
patent: 2005/0031620 (2005-02-01), Thorpe et al.
patent: 2005/0107683 (2005-05-01), Mountford et al.
patent: 2006/0035945 (2006-02-01), Attardo et al.
patent: 2006/0064003 (2006-03-01), Norfray
patent: 2006/0177378 (2006-08-01), Norfray
patent: 2006/0222591 (2006-10-01), Norfray
patent: 2007/0128114 (2007-06-01), Norfray
patent: 2007/0218006 (2007-09-01), Norfray
patent: WO 2006/036288 (2006-04-01), None
patent: WO 2006/086159 (2006-08-01), None
patent: WO 2006/107950 (2006-10-01), None
Becker et al., “Intracellular Compartments: The endoplasmic reticulum, Golgi Complex, Lysosomes, and Peroxisomes”,The World of the Cell, Third Edition, The Benjamin/Cummings Publishing Company, Ch. 9, pp. 229-270 (1996).
Bunz et al.,The Journal of Clinical Investigation, 104(3), 263-269 (Aug. 1999).
DeClerck et al.,Am. J. Pathol., 164(4), 1131-1139 (Apr. 2004).
Dzik-Jurasz, A., “Angiogenesis Imaging In Man: A Personal View From The Pharmaceutical Industry,”The British Journal of Radiology, Special Issue 2003, pp. S81-S82 (2003).
Encyclopaedia Britannica, “Cells: Their Structures and Functions”,The New Encyclopaedia Britannica, V. 15, Macropaedia, 15thedition, pp. 565-593 (1994).
Farhadi, et al., “Combined Inhibition of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Signaling: Effects on the Angiogenesis, Microcirculation, and Growth of Orthotopic Malignant Gliomas”,Journal of Neurosurgery, 102:363-370 (Feb. 2005).
Fukuoka et al., “Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer”,Journal of Clinical Oncology, vol. 21, No. 12 Jun. 15, 2003: pp. 2237-2246 DOI: 10.1200/JCO.2003.10.038.
Fuller et al., “Organelles and Vesicle Traffic,”Molecular Basis of Medical Cell Biology(a Lange medical book), Ch. 4, pp. 67-92 (1998).
Galbraith, S.M., “Antivascular Cancer Treatments: Imaging Biomarkers in Pharmaceutical Drug Development”,The British Journal of Radiology, 76 (2003), S83-S86 DOI: 10,1259/bjr/15255885.
Kauppinen, Risto A., “Monitoring Cytotoxic Tumour Treatment Response by Diffusion Magnetic Resonance Imaging and Proton Spectroscopy,”NMR Biomedicine, 2002:15:6-17; DOI:10.1002
bm.742.
Laird et al.,Cancer Research, 2000, vol. 60, pp. 4152-4160.
Leach et al., “The Assessment of Antiangiogenic and Antivascular Therapies in Early-Stage Clinical Trials Using Magnetic Resonance Imaging; Issues and Recommendations,”British Journal of Cancer(2005) 92 (9), pp. 1599-1610.
Mukherji et al.,AJNR Am. J. Neuroradio., 1996, vol. 17, pp. 1485-1490.
Nakagami et al., “Increased Choline Kinase Activity and Elevated Phosphocholine Levels in Human Colon Cancer,”Jpn. J. Cancer Res.90, 419-424, Apr. 1999.
Pollard, Thomas D., “Programmed Cell Death,”Cell Biology, Elsevier, Inc., Ch. 49, pp. 767-782 (2004); ISBN 1-4160-2388-7.
Schmitt et al.,Journal of Pathology, 187, 127-137 (1999).
Taga et al., Abstract,International Journal of Cancer98(5), 690-697 (Apr. 10, 2002).
Wojtukiewicz et al., “Contribution of the Hemostatic System to Angiogenesis in Cancer”,Seminars in Thrombosis and Hemostasis, vol. 30, No. 1 (2004) pp. 5-20.
Yamanaka et al., Abstract “Gene Therapy of Brain Tumor with Endostatin”,Drugs Today, 40(11), 931-914 (Nov. 2004).
Daly et al., “Phospholipid Metabolism in Cancer Cells Monitored by31P NMR Spectroscopy,”The Journal of Biological Chemistry, 262(31): 14875-14878 (Nov. 5, 1987).
Balkwill et al.,The Lancet, 357, 539-545 (2001).
Bianco et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Blackledge et al.,British Journal of Cancer, 90, 566-572 (2004).
Bluml et al.,Magn. Reson. Med., 42, 643-654 (1999).
Boyer,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Cappuzzo et al.I British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Cappuzzo et al.II British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Chioni et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Colman,Semin. Thromb. Hemost., 30(1), 45-61 (2004).
Cortes-Funes et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
U.S. Appl. No. 10/946,741, filed Sep. 22, 2004, Norfray.
U.S. Appl. No. 11/193,037, filed Jul. 29, 2005, Norfray.
Danielsen et al.,Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases, Marcel Dekker, Inc. Ch. 3: The clinical significance of metabolites, 23-43 (1999).
de Braud et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
de la Cruz et al.,I British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
de la Cruz et al.,II British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
de Leeuw et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Diaz-Canton,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Dieriks et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Eliason et al.,Current Drug Targets, 5, 383-388 (2004).
Engelse et al.,Semin. Thromb. Hemost., 30(1), 71-82 (2004).
Erlich,IDrugs, 6(4), 331-333 (2003).
Evelhoch,Cancer Research, 47, 3396-3401 (Jul. 1, 1987).
Fernandez et al.,Semin. Thromb. Hemost., 30(1), 31-44 (2004).
Fisher et al.,Neuroimg. Clin. N. Am.12, 477-499 (2002).
Fujimoto et al.,The 11thInternational Congress of Immunology(2001) (Abstract).
Fulham et al.,Radiology, 185, 675-686 (1992).
Gelibter et al.,British Journal of Cancer, 89, (Suppl. 2) (2003) S25-S35 Abstract.
Ger

Affiliated with

Also associated with

Rating

Method for monitoring early treatment response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for monitoring early treatment response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for monitoring early treatment response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4053280